A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial

Journal of Gynecologic Oncology ◽

10.3802/jgo.2022.33.e12 ◽

2022 ◽

Vol 33 ◽

Author(s):

Junsik Park ◽

Myong Cheol Lim ◽

Jae-Kwan Lee ◽

Dae Hoon Jeong ◽

Se Ik Kim ◽

...

Keyword(s):

Ovarian Cancer ◽

Maintenance Therapy ◽

Phase Ii Study ◽

Parp Inhibitor ◽

Gynecologic Oncology ◽

Recurrent Ovarian Cancer ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Platinum Sensitive ◽

Previously Treated

Download Full-text

A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.5501 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 5501-5501 ◽

Cited By ~ 26

Author(s):

Robert L. Coleman ◽

Danielle Enserro ◽

Nick Spirtos ◽

Thomas J. Herzog ◽

Paul Sabbatini ◽

...

Keyword(s):

Ovarian Cancer ◽

Randomized Controlled Trial ◽

Controlled Trial ◽

Gynecologic Oncology ◽

Recurrent Ovarian Cancer ◽

Phase Iii ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Randomized Controlled ◽

Platinum Sensitive

Download Full-text

Single-arm, phase II study of niraparib and bevacizumab maintenance in platinum-sensitive, recurrent ovarian cancer previously treated with a PARP-inhibitor: KGOG3056/NIRVANA-R

10.3802/jgo.2021.32.s1.o40 ◽

2021 ◽

Author(s):

Junsik Park ◽

Myong Cheol Lim ◽

Jae-Kwan Lee ◽

Dae Hoon Jeong ◽

Se Ik Kim ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Parp Inhibitor ◽

Recurrent Ovarian Cancer ◽

Platinum Sensitive ◽

Previously Treated

Download Full-text

Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: A phase II study of the Gynecologic Oncology Group

Yearbook of Obstetrics Gynecology and Women s Health ◽

10.1016/s1090-798x(08)70269-8 ◽

2007 ◽

Vol 2007 ◽

pp. 386-387

Author(s):

B.J. Monk

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Previously Treated

Download Full-text

Real world occurrence of top three clinical-trial reported adverse events of PARP inhibitor niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer, a national retrospective observational study of a 200 mg/day starting-dose cohort

Annals of Oncology ◽

10.1093/annonc/mdy285.193 ◽

2018 ◽

Vol 29 ◽

pp. viii351-viii352

Author(s):

J.R. Gallagher ◽

K.J. Heap ◽

S. Carroll

Keyword(s):

Ovarian Cancer ◽

Clinical Trial ◽

Adverse Events ◽

Observational Study ◽

Maintenance Therapy ◽

Parp Inhibitor ◽

Recurrent Ovarian Cancer ◽

Dose Cohort ◽

Platinum Sensitive ◽

Starting Dose

Download Full-text

An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: A Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION

Annals of Oncology ◽

10.1093/annonc/mdz250.069 ◽

2019 ◽

Vol 30 ◽

pp. v432

Author(s):

J.-Y. Lee ◽

J.W. Kim ◽

B.G. Kim ◽

S. Kim ◽

H.S. Kim ◽

...

Keyword(s):

Ovarian Cancer ◽

Targeted Therapy ◽

Gynecologic Oncology ◽

Recurrent Ovarian Cancer ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Platinum Resistant

Download Full-text

PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis

Gynecologic Oncology ◽

10.1016/j.ygyno.2015.08.013 ◽

2015 ◽

Vol 139 (1) ◽

pp. 59-62 ◽

Cited By ~ 25

Author(s):

Haller J. Smith ◽

Christen L. Walters Haygood ◽

Rebecca C. Arend ◽

Charles A. Leath ◽

J. Michael Straughn

Keyword(s):

Ovarian Cancer ◽

Cost Effectiveness ◽

Maintenance Therapy ◽

Parp Inhibitor ◽

Recurrent Ovarian Cancer ◽

Cost Effectiveness Analysis ◽

Platinum Sensitive ◽

Effectiveness Analysis

Download Full-text

Evaluation of Cisplatin and Cyclosporin A in Recurrent Platinum-Resistant Ovarian Cancer: A Phase II Study of the Gynecologic Oncology Group

Gynecologic Oncology ◽

10.1006/gyno.1997.4887 ◽

1998 ◽

Vol 68 (1) ◽

pp. 45-46 ◽

Cited By ~ 20

Author(s):

Alberto Manetta ◽

John A. Blessing ◽

Jean A. Hurteau

Keyword(s):

Ovarian Cancer ◽

Cyclosporin A ◽

Phase Ii ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Platinum Resistant

Download Full-text

Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: A phase II study of the Gynecologic Oncology Group

Gynecologic Oncology ◽

10.1016/j.ygyno.2005.09.009 ◽

2006 ◽

Vol 100 (2) ◽

pp. 385-388 ◽

Cited By ~ 34

Author(s):

Cheryl A. Brewer ◽

John A. Blessing ◽

Robert A. Nagourney ◽

D. Scott McMeekin ◽

Shashikant Lele ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Previously Treated

Download Full-text

Phase II Evaluation of 24-h Continuous Infusion Topotecan in Recurrent, Potentially Platinum-Sensitive Ovarian Cancer: A Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1006/gyno.2000.5755 ◽

2000 ◽

Vol 77 (1) ◽

pp. 112-115 ◽

Cited By ~ 30

Author(s):

Maurie Markman ◽

John A. Blessing ◽

Ronald D. Alvarez ◽

Parviz Hanjani ◽

Steven Waggoner ◽

...

Keyword(s):

Ovarian Cancer ◽

Continuous Infusion ◽

Phase Ii ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Platinum Sensitive

Download Full-text

Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2011.01.030 ◽

2011 ◽

Vol 121 (2) ◽

pp. 303-308 ◽

Cited By ~ 54

Author(s):

John Farley ◽

Michael W. Sill ◽

Michael Birrer ◽

Joan Walker ◽

Russell J. Schilder ◽

...

Keyword(s):

Epidermal Growth Factor Receptor ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Growth Factor Receptor ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Immunohistochemical Expression ◽

Oncology Group Study ◽

Previously Treated ◽

Epidermal Growth

Download Full-text